BioGaia AB (publ) (LON:0GTN)

Market Cap	954.05M +20.3%
Revenue (ttm)	124.84M +13.1%
Net Income	29.55M +23.9%
EPS	0.29 +24.2%
Shares Out	n/a
PE Ratio	31.93
Forward PE	26.84
Dividend	0.32 (3.41%)
Ex-Dividend Date	May 8, 2026

Volume	30
Open	123.80
Previous Close	124.25
Day's Range	123.80 - 123.90
52-Week Range	96.30 - 136.20
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 251
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GTN

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error